Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.

What Was Tested

This randomized controlled trial looks at Neurotensin.

Purpose: The high affinity receptor 1 (NTSR1) and its agonist, neurotensin (NTS), are correlated with tumor cell aggressiveness in most solid tumors.

Why It Was Studied

As chemoresistance and tumor aggressiveness are often related, the researchers decided to study the role of the NTSR1 complex within platinum-based chemotherapy responses.

The researchers measured the effects of these treatments on cell apoptosis and apoptosis-related proteins, platinum accumulation in the cell and nucleus, and the expression and localization of platinum transporters.

Who Took Part

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, women only.

NTS and NTSR1 labeling was measured in patients with ovarian cancer.Results: SR48692 enhanced the response to carboplatin in ovarian cancer cells and experimental tumors.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Neurotensin group and the comparison group should start out alike.

What Was Measured

The researchers measured the effects of these treatments on cell apoptosis and apoptosis-related proteins, platinum accumulation in the cell and nucleus, and the expression and localization of platinum transporters.

PubMed files the paper under topics including Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Carboplatin, Cell Line, Tumor, Cell Proliferation, Drug Resistance, Neoplasm and Ovarian Neoplasms.

What This Means in Plain Language

The paper is a randomized study of Neurotensin.

The publication is from 2017 (Clinical cancer research : an official journal of the American Association for Cancer Research), a journal based in United States.

More context: the Neurotensin compound page, all human trials.